ArticleDiscover oncology2025
Elevated CEP72 expression facilitates the progression of hepatocellular carcinoma and is associated with unfavorable outcomes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe specific roles and mechanisms underlying the involvement of centrosomal protein 72 (CEP72) in hepatocellular carcinoma (HCC) development are not fully understood. Thus, this study aimed to explore the influence of CEP72 on the prognosis of HCC and elucidate the underlying mechanisms involved. MATERIAL AND
methodsCEP72 expression was verified through the use of various databases, including the TCGA, GEO, CCLE, and HPA databases. Moreover, to validate the prognostic importance of CEP72 in HCC, we conducted the Kaplan‒Meier survival analyses using the GEPIA database. The connection between CEP72 and hsa-miR-139-5p was established using RT‒qPCR and Western blotting. To further evaluate the role of CEP72 and hsa-miR-139-5p in tumor regulation, we conducted the CCK8 assay, transwell migration assay, and invasion assay.
resultsThe abnormal upregulation of CEP72 in HCC tissues was identified through the use of the TCGA, GEO, CCLE, and HPA databases. Furthermore, we observed a notable correlation between elevated CEP72 expression and an unfavorable prognosis in individuals diagnosed with HCC. Furthermore, in vitro experiments further demonstrated that CEP72 expression enhanced the proliferation, migration, and invasion of HCC cells. Finally, we explored the influence of miRNAs on CEP72 expression by analyzing CEP72 expression patterns, establishing correlations, and conducting survival analysis. Interestingly, our findings confirmed that hsa-miR-139-5p was the upstream pathway regulator of CEP72 expression.
conclusionBased on our findings, CEP72 is a prognostic biomarker for HCC, and the miRNA-mediated expression of CEP72 may affect the prognosis of HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.